PCIA
SRPT icon

Prime Capital Investment Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Prime Capital Investment Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,654
Closed -$1.08M – 967
2024
Q3 		$1.08M Buy
8,654
+249
+3% +$34.4K 0.02% 427
2024
Q2 		$1.33M Sell
8,405
-3,574
-30% -$459K 0.02% 384
2024
Q1 		$1.55M Buy
11,979
+8,313
+227% +$1.02M 0.02% 388
2023
Q4 		$354K Sell
3,666
-3,763
-51% -$361K 0.01% 692
2023
Q3 		$901K Sell
7,429
-2,971
-29% -$336K 0.02% 358
2023
Q2 		$1.19M Buy
+10,400
New +$1.34M 0.02% 326

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Prime Capital Investment Advisors's SRPT Position: Q4 2024 in Review

Prime Capital Investment Advisors sold out of Sarepta Therapeutics (SRPT) in Q4 2024, closing a stake of 8,654 shares — an estimated $1.08M sold.

Prime Capital Investment Advisors first reported a position in SRPT in Q2 2023 and held it in 6 quarters. The position peaked at $1.55M in Q1 2024. 465 funds tracked by Wall St. Rank hold SRPT as of Q4 2024.

  • Prime Capital Investment Advisors reported no remaining Sarepta Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Prime Capital Investment Advisors sold 8,654 Sarepta Therapeutics shares in Q4 2024, an estimated $1.08M.
  • Prime Capital Investment Advisors first reported a position in Sarepta Therapeutics in Q2 2023 and held it in 6 quarters.
  • Prime Capital Investment Advisors's Sarepta Therapeutics position peaked at $1.55M in Q1 2024.
  • 465 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2024.

Based on Prime Capital Investment Advisors's 13F filing for Q4 2024, filed 12 Feb 2025.